Gilead Sciences Gears Up For Earnings
Gilead Sciences, Inc. (NASDAQ: GILD)
Gilead Sciences is seeing slight declines today as investors anticipate the release of the company’s Q2 earnings report tomorrow July 28th. However, I don’t think that there’s much validity in the concerns. In all reality, I’m expecting to see an overwhelmingly positive earnings report. While ABBV has entered the HCV market, and building competition could threaten revenue, Gilead Sciences has a proven history of blowing analyst expectations away; and I’m not expecting to see anything different upon this quarter’s earnings release. With that said, buying today’s declines may prove to be an incredibly profitable endeavor if earnings are indeed as I expect them to be. Currently (1:36), GILD is trading at $110.67 per share after a loss of 1.91% so far today.
Teva Pharmaceutical Industries Agrees To Acquire Allergan Generics
Teva Pharmaceutical Industries announced this morning that it has agreed to acquire the Generics arm of Allergan in a cash and stock split deal worth approximately $40.5 billion. The deal is expected to close in the first quarter of 2016; at which point, Allergan will receive $33.75 billion in cash and $6.75 billion in TEVA shares valued on July 27th, 2015. The deal has proven to be accepted in a positive light by investors with both companies’ stocks gaining today. Currently (1:44) TEVA shares are trading at $69.17 while AGN shares are trading at $329.98 after a gain of 11.75% and 7.06% respectively. The new acquisition provides TEVA with advanced abilities in the generics industry and a way to expand its pipeline of products.
MannKind Corporation Stock Continues To Fall
MannKind Corporation (NASDAQ: MNKD)
MannKind Corporation shares are currently (1:46) trading at $4.73 after a loss of 5.06%; which is generating quite the discussion. However, I wrote a post earlier today explaining why long term bulls aren’t in the least concerned about the declines. As a matter of fact, they’re buying the discounted shares. To read the post, click here. In short, MNKD investors aren’t concerned about dilution from debt and know that both Afrezza and technosphere are incredibly profitable endeavors in the long run. With that said, if you’re looking for a solid long term investment, you may want to take a close look at MNKD.
Synergy Pharmaceuticals Seems Confused As To Where To Go
Synergy Pharmaceuticals Inc (NASDAQ: SGYP)
Finally Synergy Pharmaceuticals started the day off low today before moving its way to gains. Currently (1:51), SGYP is trading at $8.10 per share after a gain of 2.34% so far today. Moving forward, I’m expecting to see relatively sideways movement while investors await the final results from the plecanatide studies. Until these results are released (in roughly a month and a half) I’m expecting to see the stock stay in the range between $7.84 and $9.76 per share. However, if previous studies are any indication, the results of the Phase 3b study are going to be overwhelmingly positive. This will prove to be the next big catalyst for the stock. So, keep your eyes peeled.
Do You Know Of Any Others?
Do you know of any other stocks that are presenting opportunities in biotech? If so, let us know in the comments below!